Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.53 |
| ▸ | MAOA | P21397 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | CALML3 | P27482 | 1/20 | 0.49 |
| ▸ | SDHA | P31040 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761391 | 0.90 | F10 (0.54) | F10 | |
| SCHEMBL5763117 | 0.88 | F10 (0.54) | F10ABCB11 | |
| SCHEMBL5761171 | 0.85 | MAOA (0.58) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5763666 | 0.85 | F10 (0.48) | F10 | |
| SCHEMBL5761728 | 0.84 | MAOA (0.52) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL5763058 | 0.83 | MAOA (0.54) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6395123 | 0.83 | F10 (0.56) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6395125 | 0.83 | F10 (0.56) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6403102 | 0.83 | MAOA (0.62) | F10MAOAMAOBLMNAPTGS1 | |
| SCHEMBL6403105 | 0.83 | MAOA (0.62) | F10MAOAMAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094900-B2 | N-Aryl-2-oxazolidinones and their derivatives | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-08-22 | — | — | US | claimed |
| EP-1539745-B1 | N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-29 | — | — | EP | claimed |
| EP-1539745-A1 | N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-06-15 | — | — | EP | claimed |
| US-20040072873-A1 | N-Aryl-2-oxazolidinones and their derivatives | GADWOOD ROBERT C (US) | 2004-04-15 | — | — | US | claimed |
| WO-2004014897-A1 | N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-7094900-B2 | N-Aryl-2-oxazolidinones and their derivatives | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1539745-B1 | N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES | PHARMACIA & UPJOHN CO LLC (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1539745-A1 | N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040072873-A1 | N-Aryl-2-oxazolidinones and their derivatives | GADWOOD ROBERT C (US) | 2004-04-15 | — | — | US | disclosed |
| WO-2004014897-A1 | N-ARYL-2-OXAZOLIDINONES AND THEIR DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072873-A1 | N-Aryl-2-oxazolidinones and their derivatives | OXA1L, NDUFS7, NDUFS6 | F10 4763/4885MAOA 854/4885MAOB 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.